
To evaluate whether the safety and efficacy of zzso treatments in elderly patients with rheumatic diseases is similar than the safety and efficacy of the same drugs in younger zzso 

zzso zzso We performed a systematic search in zzso zzso zzso zzso and the Cochrane Library zzso zzso published in the American and European rheumatology zzso and articles in zzso zzso were also zzso 

Ten studies fulfilled the inclusion zzso Studies show a similar efficacy in elderly and younger zzso The differences between the young and the elderly regarding zzso reductions before and after are very zzso zzso in the zzso et al study and zzso in the zzso et al study, as well as in the before and after zzso zzso zzso et zzso zzso zzso et zzso and zzso zzso et zzso events reported in elderly and younger patients are zzso and zzso respectively with zzso as reported by zzso zzso vs zzso zzso as reported by zzso and the rate of withdrawal due to an adverse event was zzso vs zzso with zzso zzso zzso vs zzso zzso with zzso and zzso and zzso with no significant p value, as reported by zzso 

The information to assess the efficacy and safety of zzso therapy in elderly patients was obtained in all cases from zzso analyses and therefore bias is zzso We can say, with a low to moderate level of evidence, that elderly patients undergoing zzso treatments have a higher number of adverse events, and similar zzso when compared with younger zzso 

